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Background: Patients with COPD may be prescribed multiple inhalers as part of their treat-
ment regimen, which require different inhalation techniques. Previous literature has shown that 
the effectiveness of inhaled treatment can be adversely affected by incorrect inhaler technique. 
Prescribing a range of device types could worsen this problem, leading to poorer outcomes in 
COPD patients, but the impact is not yet known.
Aims: To compare clinical outcomes of COPD patients who use devices requiring similar 
inhalation technique with those who use devices with mixed techniques.
Methods: A matched cohort design was used, with 2 years of data from the Optimum 
Patient Care Research Database. Matching variables were established from a baseline year of 
follow-up data, and two cohorts were formed: a “similar-devices cohort” and a “mixed-devices 
cohort”. COPD-related events were recorded during an outcome year of follow-up. The pri-
mary outcome measure was an incidence rate ratio (IRR) comparing the rate of exacerbations 
between study cohorts. A secondary outcome compared average daily use of short-acting beta 
agonist (SABA).
Results: The final study sample contained 8,225 patients in each cohort (mean age 67 [SD, 10], 
57% males, 37% current smokers). Patients in the similar-devices cohort had a lower rate of 
exacerbations compared with those in the mixed-devices cohort (adjusted IRR 0.82, 95% 
confidence interval [CI] 0.80–0.84) and were less likely to be in a higher-dose SABA group 
(adjusted proportional odds ratio 0.54, 95% CI 0.51–0.57).
Conclusion: COPD patients who were prescribed one or more additional inhaler devices 
requiring similar inhalation techniques to their previous device(s) showed better outcomes than 
those who were prescribed devices requiring different techniques.
Keywords: chronic obstructive pulmonary disease, inhalation technique, exacerbations, inhaler 
devices, observational, matched cohort
Introduction
COPD is a common lung disease characterized by variable day-to-day respiratory 
symptoms. Management is aimed at both improving symptom control and preventing 
or reducing exacerbations.1 Inhalers deliver medication directly to the lungs and many 
types of inhaler devices are available. Different devices may require unique inhalation 
techniques to ensure the medication is delivered optimally.2 For example, metered-dose 
inhalers (MDIs) require a slow and steady inhalation for adequate lung deposition.3,4 In 
contrast, inhalation when using dry-powder inhalers (DPIs) must be quick to disaggregate 
and dispense the powder and deliver the required dose.4,5 Further variations exist, in the 
dose-loading mechanisms of inhalers (device preparation) and in the resistance to airflow 
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within the device. There is also a negative impact of exhaling 
into the device after priming, which impacts drug delivery for 
some but not all devices.6 With such precision required, it is 
not surprising that errors in inhalation technique are common 
and can lead to reduced effectiveness of treatment.7–13 Incor-
rect inhalation technique is well-recognized as a problem with 
patients using only one inhaler, and it could be compounded 
when introducing additional inhalers into a treatment regimen. 
Use of multiple inhalers compared to single inhalers has been 
shown to have an adverse effect on outcomes, even without 
consideration of inhalation technique.14,15
Despite suggestions that mixing devices could be detri-
mental to patient outcomes,2 no one has yet investigated its 
real impact in COPD. For such a common illness, with high 
mortality and significantly impaired quality of life,16,17 it is 
important for research to highlight where problems lie, to 
allow management guidelines to be addressed accordingly.
This study used real-life observational data to compare 
and quantify the COPD outcomes for two types of patient – 
those who use multiple inhaler devices with similar inhalation 
technique and those who use multiple inhaler devices with 
mixed inhalation techniques.
Materials and methods
Data source and permissions
For this study, data from the Optimum Patient Care Research 
Database (OPCRD)18 – a primary care database containing 
anonymized, routinely-recorded clinical data from over 
2 million patients – were used. The data originated from 
over 550 General Practices (GPs) across the UK and was 
supplemented by patient-completed questionnaire data for 
approximately 10% of patients with asthma and COPD. The 
OPCRD has ethical approval from the National Health Service 
Research Authority to hold and process anonymized research 
data (Research Ethics Committee reference: 15/EM/0150). 
This study was conducted to standards recommended for 
observational research19 and was approved by the Anonymized 
Data Ethics Protocols and Transparency committee – the 
independent scientific advisory committee for the OPCRD; 
patient consent was not required due to the retrospective 
nature of this study, as approved by this committee. This 
study is registered with the European Network of Centres for 
Pharmacoepidemiology and Pharmacovigilance.20
study design
A historical, matched cohort study design was used, creating 
two study cohorts that differed in terms of the inhaler devices 
used by patients. The two cohorts were classified after an 
additional COPD therapy was prescribed to patients, via a 
separate inhaler device. Prior to this additional prescription, 
if patients used more than one device, these multiple devices 
required similar inhalation technique. After the additional 
prescription, patients were allocated to either the “similar-
devices cohort”, where patients used two or more inhalers that 
required similar inhalation technique or the “mixed-devices 
cohort”, where the patients used two or more inhalers, with 
at least one inhaler requiring a largely different inhalation 
technique compared to their other device(s). For the main 
analysis, the inhalers were categorized as “similar” if they 
were all aerosols (MDI or a soft mist inhaler) or all DPIs. 
A patient using any combination of these two categories 
would be allocated to the “mixed-devices” cohort. Hence, 
a patient using at least one MDI alongside at least one DPI 
was allocated to the “mixed-devices” category.
To investigate the impact of a more stringent categorization, 
a sensitivity analysis was also carried out. Here, the DPIs were 
distinguished further and devices were considered “mixed” if 
they varied by the level of resistance to airflow through the 
device or by the number of doses that can be loaded into the 
device (ie, single dose versus multiple dose). Table 1 shows the 
specific categorization of devices for each type of analysis.
This study consisted of two continuous years of data, 
within the period 2008–2015, on either side of an index date. 
Table 1 Device categorization used to form study cohorts
Categorization of devicesa
Main analysis Sensitivity analysis
Aerosols: manual-activated MDI, 
manual-activated MDI with spacer, 
breath-actuated MDI and soft 
mist inhaler (pMDIs, CFC-free 
inhalers, breath-actuated inhalers, 
Clenil modulite, pMDIs + pacer, 
autohaler, easibreathe, respimat)
Aerosols: same as in main 
analysis
DPIs: single-dose capsule DPI 
(Breezhaler, aerolizer, handihaler), 
multi-dose DPI with medium 
resistance (accuhaler [Diskus], 
novolizer, genuair, elipta) and 
multi-dose DPI with medium–high 
or high resistance (Turbohaler, 
Clickhaler, Pulvinal, Twisthaler, 
easyhaler, Duoresp)
Single-dose capsule DPI 
(Breezhaler, aerolizer, 
handihaler)
Multi-dose DPI with 
medium resistance: 
(accuhaler [Diskus], 
novolizer, genuair, ellipta)
Multi-dose DPI with 
medium–high or high 
resistance (Turbohaler, 
Clickhaler, Pulvinal, Twisthaler, 
easyhaler, Duoresp)
Note: aDevices from within categories (identified with headings in bold) are considered 
“similar” and devices from more than one category are considered “mixed”.
Abbreviations: DPI, dry-powder inhaler; MDI, metered dose inhaler; pMDI, 
pressurized metered dose inhaler.
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The index date was identified as the point at which a 
prescription of additional COPD therapy was made, which 
required the use of an inhaler device separate from the cur-
rent COPD treatment of that patient. The year preceding 
this date was the baseline year and the subsequent year was 
the outcome year. Study cohorts (“similar” versus “mixed”) 
were matched in a ratio of 1:1 to minimize differences that 
could affect the comparison of study outcomes. Matching 
variables were identified through comparison of baseline 
variables between unmatched cohorts and by assessing 
the variables that were most predictive of COPD outcome 
(number of exacerbations).
Inclusion and exclusion criteria
Patient records were subject to the following inclusion cri-
teria: record of diagnosis of COPD; at least 40 years of age 
at the date of initial prescription; an initial prescription of 
COPD therapy, including short-acting beta agonist (SABA), 
short-acting muscarinic agonist (SAMA), long-acting beta 
agonist (LABA) or long-acting muscarinic agonist, which 
could be given alone or in combination, but must be given in 
“similar” devices if in combination; one or more prescriptions 
of additional COPD therapy via a separate inhaler device, on 
the index date or during the outcome year (a change in inhaler 
device, rather than the addition of a device, does not fall under 
the inclusion criteria); at least 2 years of continuous medical 
records from GP (at least 1 year of which is when patient is 
on initial therapy and 1 year on additional therapy).
Patients were excluded if they had “mixed” devices prior 
to the index date or if they had at least one prescription for 
nebulizer prior to the index date, as this is another category 
of device altogether.
Outcome measures
The primary outcome was the rate of moderate/severe COPD 
exacerbations21 during the outcome year, comparing the 
similar-devices cohort to the mixed-devices cohort. Details 
of exacerbation criteria are summarized in the notes of 
Table 2. The comparison of exacerbation rates was done by 
estimating an adjusted incidence rate ratio (IRR) – adjusted 
by factors that were not used in the matching process but 
were found to be different between cohorts at baseline. 
A secondary outcome was the average daily SABA use dur-
ing the outcome year, which was compared between study 
cohorts. A proportional odds ratio (OR) was estimated, 
comparing the odds of being in higher SABA dose categories. 
Again, this was adjusted by important factors that differed 
at baseline.
statistical analysis
Summary statistics were computed for baseline character-
istics of study cohorts, including demographic variables, 
COPD-related characteristics and therapies, comorbidities 
and co-medications. Variables found to be significantly dif-
ferent between cohorts (P,0.05) were potentially used as 
adjusting variables for the primary and secondary analyses. 
If these variables were found to be unimportant in the mul-
tivariate models for the primary/secondary outcomes, they 
Table 2 Baseline demographic characteristics and COPD severity 
of study cohorts
Patient characteristics Similar-devices  
cohort (n=8,225)
Mixed-devices  
cohort (n=8,225)
Demographic characteristics
age (years)
40–60, n (%) 1,856 (22.6) 1,856 (22.6)
61–80, n (%) 5,863 (71.3) 5,863 (71.3)
.80, n (%) 506 (6.2) 506 (6.2)
Mean (sD) 67.3 (9.9) 67.2 (9.7)
Male, n (%) 4,645 (56.5) 4,645 (56.5)
Body mass index (kg/m2)
,18.5, n (%) 151 (1.8) 151 (1.8)
18.5–24.9, n (%) 2,892 (35.2) 2,892 (35.2)
25–29.9, n (%) 2,981 (36.2) 2,981 (36.2)
$30, n (%) 2,201 (26.8) 2,201 (26.8)
Mean (sD) 27.4 (6.1) 27.4 (5.7)
smoking status (closest  
to index date)
nonsmoker, n (%) 584 (7.1) 584 (7.1)
Current smoker, n (%) 3,029 (36.8) 3,029 (36.8)
ex-smoker, n (%) 4,612 (56.1) 4,612 (56.1)
COPD severity
FeV1 % predicted
a
gOlD 1: FeV1 $80  
(mild), n (%)
717 (8.7) 717 (8.7)
gOlD 2: 50# FeV1 ,80  
(moderate), n (%)
4,659 (56.6) 4,659 (56.6)
gOlD 3: 30# FeV1 ,50  
(severe), n (%)
2,003 (24.4) 2,003 (24.4)
gOlD 4: FeV1 ,30  
(very severe), n (%)
846 (10.3) 846 (10.3)
Mean (sD) 55.9 (22.6) 55.7 (22.5)
COPD exacerbationsb
0, n (%) 4,226 (51.4) 4,226 (51.4)
1, n (%) 2,394 (29.1) 2,394 (29.1)
2, n (%) 972 (11.8) 972 (11.8)
$3, n (%) 633 (7.7) 633 (7.7)
Notes: Variables were not compared statistically as all were used in matching 
process. aFeV1 % predicted grouped by GOLD classifications; 
bmoderate/severe 
exacerbations were identified by acute course of oral corticosteroids (OCS) 
unlikely to be maintenance therapy, antibiotics prescribed within a lower respiratory 
consultation or admission to hospital/emergency department for COPD or 
following lower respiratory consultation. Further details of prescriptions of OCs 
and antibiotics are found in Table 3.
Abbreviations: sD, standard deviation; FeV1, forced expiratory volume in 1 second; 
gOlD, global initiative for chronic Obstructive lung Disease.
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were removed to arrive at the most parsimonious model. 
Confounders were checked for co-linearity using Spearman’s 
correlation coefficients for linear relationships, and plots and 
univariate logistic regression models for non-linear relation-
ships. If colinearity was observed between several adjusting 
variables in the primary and secondary multivariate models, 
the most significant of the variables was retained in the 
model. Through this process, all available adjusting variables 
that impacted the unadjusted results were included. Summary 
statistics were also computed for COPD outcomes, that is the 
number of exacerbations and average daily SABA use.
The primary analysis fitted a negative binomial regression 
model to estimate the IRR for rate of exacerbations, with 
95% confidence intervals (CIs). A conditional, fixed effects 
version of this model was applied to adjust for confounders 
and account for overdispersion in the data.
For the secondary analysis, average daily SABA use dur-
ing the outcome year was calculated as follows:
 
Number of inhalers*doses per inhaler
dosage g
365
× ( )µ
 
This was grouped into five categories with cutoff points 
chosen using quintiles. This strengthened the model used 
to investigate the secondary outcome by ensuring adequate 
numbers of patients in each category. The model used was an 
ordinal logistic regression model to estimate the proportional 
OR (with 95% CI) of being prescribed a higher average daily 
SABA drug dosage, comparing the similar-devices cohort 
to the mixed-devices cohort. Standard errors were adjusted 
by appropriate confounders.
The aforementioned primary and secondary analyses 
were repeated for the sensitivity analysis mentioned previ-
ously, where the matched cohorts were based on an alterna-
tive categorization of devices. A further sensitivity analysis 
was carried out on a subgroup of the study sample, as deter-
mined by the COPD treatment received during the outcome 
year. Patients were categorized according to the combina-
tion of therapy received, for example, LABA ± SAMA ± 
SABA, and inhaled corticosteroids (ICS) ± SAMA ± SABA. 
The largest group was analyzed separately to investigate 
whether the effect found in the main analysis remained in 
this subgroup.
The level of statistical significance was set at 5% 
(ie, P,0.05). No prospective power calculation was carried 
out since the sample size was determined by the number of 
eligible patients in the OPCRD according to the inclusion 
criteria and by the number who could then be matched exactly 
to a patient in the opposite cohort. All categorization and 
coding of variables, and definition of COPD-related vari-
ables, were approved by the steering committee. Analyses 
were carried out using IBM SPSS Statistics version 22 and 
Stata version 14.
Results
Patients
After applying inclusion and exclusion criteria, 71,517 
patients with COPD were identified from the OPCRD. 
This number was reduced to 52,378 following removal of 
duplicates and of records with missing observations for the 
matching variables. The chosen matching variables were 
age, sex, body mass index (BMI), smoking status, forced 
expiratory volume in 1 second (FEV
1
) % predicted, number 
of moderate/severe exacerbations during baseline year, num-
ber of types of COPD treatment, having active asthma and 
index year. After 1:1 matching, there were 8,225 patients in 
each study cohort (Figure 1). For the alternative categoriza-
tion of devices, (Table 1) there were 7,545 patients in each 
matched cohort.
Patients in both cohorts had a mean age of 67 years 
(SD ≈10), with the majority (71.3%) aged between 61 and 
80 years (Table 2). Just over half were males (56.5%), mean 
BMI was 27.4 (SD ≈6) and 36.8% were current smokers at 
the time of index date. In the baseline year, mean FEV
1
 % 
predicted was ~56 (SD ≈23) and 51.4% of patients had zero 
moderate or severe exacerbations, while 7.7% had 3 or more 
exacerbations.
During the baseline year, 17.5% of patients in the similar-
devices cohort and 18.9% in the mixed-devices cohort 
required one course of acute oral corticosteroids (OCS) 
(Table 3). Equivalent percentages for at least one course of 
antibiotics with a lower respiratory consultation were 21.9% 
and 21.3%. Over half of patients in each cohort required at 
least one COPD-related consultation. The majority of patients 
in each cohort were receiving only one medication type of 
COPD treatment (53.2%), and 40% were receiving two types. 
Here, medication type refers to the type of COPD therapy, 
whether inhaled (eg, SABA and ICS) or in tablet form (eg, 
theophylline and mucolytes). Comparison between cohorts 
showed statistically significant differences, in that more 
patients in the mixed-devices cohort needed; at least one 
acute OCS course; three or more antibiotics courses; higher 
SABA inhaler usage per day and at least one COPD-related 
consultation, during the baseline year. Due to these signifi-
cant differences, which could be interpreted as an increased 
likelihood of exacerbation in the mixed-devices cohort, acute 
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course of OCS, course of antibiotics, SABA use and COPD-
related consultations were investigated as potential adjusting 
variables in the primary outcome model.
Information about patient comorbidities, baseline co-
medications and other measures of COPD severity is given 
in Table S1. Significant differences (in percent) between 
matched cohorts were found in patients with rhinitis (less 
in mixed-devices cohort), eczema (less in mixed-devices 
cohorts), osteoporosis (more in mixed-devices cohorts) and 
pneumonia (more in mixed-devices cohorts). These comorbid-
ities, as well as statin-taking (more prevalent in mixed-devices 
cohort), were investigated as potential adjusting variables in 
the main analysis. Significant differences were also observed 
for modified Medical Research Council dyspnea scale score 
and Global initiative for chronic Obstructive Lung Disease 
classification, but neither of these was used as a matching or 
adjusting variable due to the number of missing observations. 
Specific combinations of COPD treatment during the baseline 
year are given in Table S2.
Primary outcome
The number of moderate/severe exacerbations during the 
outcome year declined in both cohorts with respect to the 
baseline year, with 58.5% of patients in the similar-devices 
cohort and 53.4% in the mixed-devices cohort, having zero 
exacerbations in the outcome year (Table 4). After adjustment 
by confounders, including course of antibiotics, asthma diag-
nosis and paracetamol use, the rate of exacerbations was lower 
in the similar-devices cohort compared with the mixed-devices 
cohort, with an IRR of 0.82 (95% CI 0.80–0.84; Figure 2).
secondary outcome
During the outcome year, 18.9% of patients in the similar-
devices cohort and 26.4% in the mixed-devices cohort 
used .550 µg SABA per day (Table 4). In general, patients 
in the similar-devices cohort were less likely to be in a higher 
SABA dose group compared to mixed-devices cohort, with 
an adjusted proportional OR of 0.54 (95% CI 0.51–0.57; 
Figure 2).
sensitivity analyses
The first sensitivity analysis was carried out on study cohorts 
that were based on an alternative categorization of inhaler 
devices – one that included differences in DPIs (n=7,545 in 
each cohort). The similar-devices cohort based on DPI use 
was further categorized into DPIs which were single-dose 
capsule products, DPIs with medium resistance and DPIs 
with medium to high and high resistance (as classified by 
Laube et al4). Results for the primary outcome were similar 
to the main analysis, with the similar-devices cohort showing 
a reduced rate of moderate/severe exacerbations compared 
to the mixed-devices cohort (IRR 0.82, 95% CI 0.78–0.86; 
23&5'2SWLPXP3DWLHQW&DUH5HVHDUFK'DWDEDVH
8QPDWFKHGFRKRUWQ 
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•&DWHJRUL]DWLRQE\LQKDOHUW\SHV
6LPLODUGHYLFHVFRKRUWSUHPDWFKLQJQ 
6LPLODUGHYLFHVFRKRUWSRVWPDWFKLQJQ 
•PDWFKLQJE\UHOHYDQWYDULDEOHVD
0L[HGGHYLFHVFRKRUWSUHPDWFKLQJQ 
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Figure 1 Flow diagram showing study cohorts derived from Optimum Patient Care research Database.
Notes: aMatching variables included are as follows: age, sex, body mass index, smoking status, forced expiratory volume in 1 second % predicted, number of moderate/
severe exacerbations during baseline year, number of types of COPD treatment, active asthma and index year. Matching variables were derived from exploratory analysis 
of 1 year of baseline data.
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outcome year, which was ICS ± LABA ± SAMA ± SABA 
(Table S3). This subgroup consisted of 3,680 patients in 
the similar-devices cohort (44.7% of the total patients) and 
2,859 patients in the mixed-devices cohort (34.8% of the total 
patients). Again, the rate of moderate/severe exacerbations 
was reduced in the similar-devices cohort compared with the 
mixed-devices cohort but to a lesser extent than in the main 
analysis (IRR 0.90, 95% CI 0.82–0.99; Figure S2). There 
was also a weaker effect than the main analysis on odds of 
being in a higher group of daily SABA dose, though it was 
still significant in favor of similar-devices cohort (OR 0.70, 
95% CI 0.64–0.76).
Combining both sensitivity analyses, that is, the largest 
treatment combination subgroup after the alternative catego-
rization of devices, led to similar results (Figure S3).
Discussion
This study demonstrates that patients with COPD who were 
prescribed inhalers requiring similar inhalation technique 
to the inhalers they were already using had better COPD 
outcomes than patients whose additional inhalers required 
a different technique. Specifically, patients using similar 
devices had a lower rate of exacerbations and were less likely 
to use higher doses of SABA medication, suggesting better 
symptom control. This effect was present after matching/
adjustment of important patient characteristics and common 
predictors of future exacerbations.
There is a wide range of inhalers for COPD on the mar-
ket, and no pharmaceutical company manufactures all types 
Table 3 Baseline COPD-related therapy of study cohorts
COPD-related 
therapies
n (%) P-valuea
Similar-
devices cohort 
(n=8,225)
Mixed-devices 
cohort 
(n=8,225)
acute oral 
corticosteroid (OCs) 
coursesb
0.019
0 6,010 (73.1) 5,882 (71.5)
1 1,437 (17.5) 1,557 (18.9)
2 489 (6.0) 487 (5.9)
$3 289 (3.5) 299 (3.6)
antibiotic courses with 
a lower respiratory 
consultationc
0.031
0 5,111 (62.1) 5,205 (63.3)
1 1,803 (21.9) 1,755 (21.3)
2 782 (9.5) 725 (8.8)
$3 529 (6.4) 540 (6.6)
number of types of 
COPD treatment
na
1 4,374 (53.2) 4,374 (53.2)
2 3,289 (40.0) 3,289 (40.0)
3 545 (6.6) 545 (6.6)
4 17 (0.2) 17 (0.2)
saBa inhaler usage 
(µg per day)
,0.001
0 735 (8.9) 839 (10.2)
1–55 2,174 (26.4) 1,896 (23.1)
55–165 1,927 (23.4) 1,959 (23.8)
165–440 1,560 (19.0) 1,588 (19.3)
.440 1,829 (22.2) 1,943 (23.6)
COPD-related 
consultations
,0.001
0 3,532 (42.9) 3,257 (39.6)
1 2,476 (30.1) 2,501 (30.4)
$2 2,217 (27.0) 2,467 (30.0)
Notes: aP-values are from conditional logistic regression models. ball acute OCs 
courses that are definitely not maintenance therapy and/or all courses where 
dosing instructions suggest exacerbation treatment (eg, a reducing dose or a fixed 
term specified) and/or all courses with no dosing instructions, but unlikely to be 
maintenance therapy due to prescription strength or frequency of prescriptions. 
clower respiratory consultation refers to lower respiratory diagnostic codes 
(including asthma, COPD and lrTI read codes), or asthma/COPD review codes 
excluding any monitoring letter codes, or lung function and/or asthma monitoring, 
and any additional respiratory examinations, referrals, chest X-rays, or events. 
b,cWhere .1 OCs course/antibiotic prescription occurred within 2 weeks of each 
other, these events were considered to be the result of the same course. na 
indicates that no comparison was done as variable was used for matching.
Abbreviations: lrTI, lower respiratory tract infection; saBa, short-acting beta 
agonist.
Table 4 COPD outcomes in each study cohort during the 
outcome year
COPD outcome n (%)
Similar-devices  
cohort (n=8,225)
Mixed-devices  
cohort (n=8,225)
number of  
exacerbations
0 4,810 (58.5) 4,389 (53.4)
1 1,985 (24.1) 2,004 (24.4)
2 828 (10.1) 959 (11.7)
3+ 602 (7.3) 873 (10.6)
average daily  
saBa dosagea (µg)
0 1,437 (17.5) 524 (6.4)
,110 1,742 (21.2) 1,698 (20.6)
111–300 1,706 (20.7) 1,847 (22.5)
301–550 1,788 (21.7) 1,984 (24.1)
.550 1,552 (18.9) 2,172 (26.4)
Notes: aaverage daily saBa dosage grouped by quintiles, according to similar-
devices cohort.
Abbreviation: saBa, short-acting beta agonist.
Figure S1). Results for the secondary analysis showed the 
same effect as in the main analysis, but with slightly weaker 
magnitude: similar-devices cohort was less likely to be in a 
higher category of average SABA dose per day during the 
outcome year (OR 0.61, 95% CI 0.57–0.64).
The second sensitivity analysis was applied to the larg-
est subgroup of COPD treatment combination during the 
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of available inhaled treatment. This leads to inhaler devices 
requiring different inhalation techniques. Previous literature 
has hypothesized that mixing inhaler devices could cause 
confusion and have an adverse effect on patient outcomes 
in COPD and asthma.2 The main finding of the current study is 
consistent with this hypothesis and with a recent asthma study 
that had a similar research question comparing patients whose 
reliever and controller devices were both breath-actuated 
inhalers (BAIs) to patients with BAI as controller and MDI 
as reliever.22 They found that the patients with only BAIs 
were more likely to achieve asthma control during 1 year of 
follow-up than the patients with different inhalers. The current 
results are also consistent with studies showing that simpler 
treatment regimens are more effective in COPD. Large obser-
vational studies by Yu et al14 and Chrischilles et al15 found that 
patients using multiple inhaler devices, rather than a single 
device, had increased hospital resource utilization and number 
of exacerbations. Although the cohorts in the current study 
were comparable in terms of number of devices, the trend 
toward simplicity is common in both scenarios.
The most likely reason for reduced effectiveness in 
patients with mixed devices is that the variation in inhalation 
technique leads to inhalation errors. Suboptimal inhalation 
results in medication not being delivered to the target area 
adequately. In a study involving asthma and COPD patients, 
inhaler errors were associated with several adverse outcomes, 
including hospitalization.23 Errors may be more common in 
specific types of patient. For example, MDIs require good 
coordination to ensure actuation coincides with (slow) inha-
lation. In contrast, although DPIs are breath-actuated, they 
require rapid and forceful inhalation. Additionally, errors 
have been shown to increase with age.23,24 As respiratory 
function is reduced in older people, this may impact the abil-
ity to effectively use a DPI. MDI use may also be affected 
with increasing age due to reduced hand strength to correctly 
push the inhaler. However, cohorts in the current study were 
well matched in terms of age and comorbidity, so it is likely 
that common errors would be present in both cohorts, whether 
devices were mixed or not. Instead, a possible explanation to 
the observed difference between mixed-devices and similar-
devices cohorts is that as errors are common when using one 
type of device, there may be even more errors when there 
are several types of device in use.
The main analysis suggested that patients using all MDI 
or all DPI devices have better outcomes; the study then went 
further by considering specific types of DPI. This distinction 
may be more meaningful from the patient perspective, par-
ticularly with regard to dose preparation. For example, multi-
dose DPIs have a mechanism that must be rotated to load the 
medication and so is an additional method of use that must be 
learned even if the patient is familiar with single-dose DPIs. 
The current study results showed that the impact on COPD 
outcomes for this alternative categorization of devices was 
similar to the main analysis. This suggests that the essential 
differences between types of DPI may be as important as the 
more obvious differences between MDIs and DPIs and could 
act as a barrier to correct inhaler use. Differences in general 
could also act as a barrier to patient adherence, in turn reduc-
ing effectiveness. More complex treatment regimens may 
be off-putting to patients. For example, a study by Yu et al25 
found that patients using multiple inhalers were less likely 
to be adherent than those using a single inhaler.
5HIHUHQFHPL[HGGHYLFHVFRKRUW
)DYRUVVLPLODUGHYLFHV
0RGHUDWHVHYHUHH[DFHUEDWLRQV,55
$YHUDJHGDLO\6$%$GRVH25
±
±
 
$GMXVWHGDLQFLGHQFHUDWHUDWLR,55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Figure 2 effect of similar versus mixed devices on primary and secondary COPD outcomes.
Notes: aIrr adjusted by antibiotic course, asthma diagnosis and paracetamol use. Or adjusted by baseline saBa and osteoporosis.
Abbreviations: CI, confidence interval; SABA, short-acting beta agonist.
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The current study observed an 18% reduction in exacer-
bation rate when inhalers with similar techniques were used 
and observed that 41%–45% of patients in either cohort had 
at least one moderate/severe exacerbation during the outcome 
year. This 18% reduction, even if modest, is important in 
relieving the burden on the COPD patient population. Further, 
it will have an impact on the high health care costs.26
The strength of this study is that it analyzed a large 
sample from a high-quality database, representative of the 
real-life COPD patient population. Randomized controlled 
trials (RCTs) often study a highly selected patient sample 
and the results cannot necessarily be extrapolated to the 
general patient population; this makes observational studies 
an essential contribution to evidence.27 Further, in contrast 
to RCTs where the length of follow-up is often limited, this 
study obtained 1-year follow-up data, which could capture 
relatively infrequent events such as exacerbations. Likewise, 
baseline characteristics were not based on a cross-sectional 
view from a specified date, but on 1 year of baseline data 
from multiple index dates to form comparable cohorts.
We addressed the main drawback of an observational 
study, such as lack of randomization, by applying population 
matching to the study design and adjustment for confounders 
to analyses. This was especially important as the baseline 
comparisons showed that patients in the mixed-devices 
cohort (though the devices were not mixed during the base-
line period) appeared to be less controlled than those in the 
similar-devices cohort. Without allowing for these initial 
differences, the comparison of outcomes would be biased. 
To allow this, confounding was minimized as much as pos-
sible by adjusting statistical models by factors such as COPD 
severity and comorbidities. This was also important as the 
study sample, by definition, were patients whose symptoms 
were increasing to the point where additional treatment was 
required (ie, the index date). Number of treatment types 
was also used as a matching variable; an imbalance here 
could have caused bias in terms of adherence. Relevant 
sensitivity analyses were carried out to test the robustness 
of the main results. This included subgroup analysis in the 
largest treatment combination group, which confirmed that 
the main effect was not being driven by less common treat-
ment combinations.
Limitations of the current study include the possibility 
of residual confounding, which may be present despite the 
measures described earlier. An unmeasured confounder that 
may have introduced bias is any cognitive disorder in the 
patients. This is relevant in an intervention that depends on 
knowing how to use multiple devices. However, this bias 
will have been reduced somewhat when allowing for age 
and co-medications. This study did not take into account 
specific types of medication, which may be a source of bias. 
Salbutamol, for example, is used frequently in reliever MDIs, 
whereas controller medications are more diverse. This is 
something to be considered in future studies.
This study did not capture information about patient 
adherence or about specific errors in inhaler use. Such data 
may have offered a useful insight, as these factors may drive 
the effect on outcomes. It was considered outside the scope 
of the primary research question in this study; however, it 
may be of interest to investigate adherence in future studies, 
especially with evidence suggesting variation in level of 
adherence between types of device.28 A further limitation 
of this study is that patients were not distinguished within 
cohorts by their device type, that is, the proportion of patients 
in the similar-devices cohort using only DPIs or only MDIs 
is unknown. This may have led to differences between 
cohorts if it was the case that the mixed-devices cohort had 
a much larger proportion of DPI users than the similar-
devices cohort. Differences could arise due to variation in 
adherence levels or inhaler errors made with increasing age, 
as mentioned previously.
There have already been calls for more careful consider-
ation to be given to the choice of prescribed inhaler devices 
in COPD.29 The Aerosol Drug Management Improvement 
Team suggested a strategy in 2011,29 which offered physi-
cians guidelines for various aspects of COPD management, 
including choice of inhaler. A previous study found that 
physicians usually base inhaler choices on the age, skills 
and physical capacity of their patients.30 The current study 
provides evidence to suggest that prescribing inhalers that 
require similar inhalation technique should be a further con-
sideration when choosing additional therapies.
Conclusion
After being prescribed one or more additional inhaler devices, 
COPD patients who used multiple devices that required 
similar inhalation techniques had more favorable clinical 
outcomes in comparison with patients who used devices 
that required mixed inhalation techniques. This relationship 
existed after controlling for likely confounders, suggesting 
that mixing devices may inherently lead to incorrect use 
and/or reduced patient adherence. This is an intuitive result, 
consistent with numerous sources in the literature. However, 
similar studies on different data sets would be useful in order 
to consolidate evidence and support recommendations in 
primary care management.
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Table S1 Comorbidities, baseline co-medications and COPD classifications in each study cohort
Patient characteristics n (%) P-valuee
Similar-devices  
cohort (n=8,225)
Mixed-devices  
cohort (n=8,225)
Comorbidities
asthmaa 1,870 (22.7) 1,926 (23.4) 0.17
asthma (active)a,c 896 (10.9) 896 (10.9) na
Diabetesa 1,388 (16.9) 1,356 (16.5) 0.487
Oral thrushb 49 (0.6) 63 (0.8) 0.187
rhinitisa 677 (8.2) 584 (7.1) 0.006
rhinitis (active)b,d 345 (4.2) 331 (4.0) 0.579
eczemaa 1,162 (14.1) 1,143 (13.9) 0.665
eczema (active)b,d 223 (2.7) 181 (2.2) 0.034
Cardiovascular diseasea 2,811 (34.2) 2,817 (34.3) 0.918
heart failurea 409 (5.0) 404 (4.9) 0.918
Ischemic heart diseasea 1,693 (20.6) 1,719 (20.9) 0.605
hypertensionb 1,247 (15.2) 1,192 (14.5) 0.223
Gastroesophageal reflux diseasea 586 (7.1) 586 (7.1) .0.99
gerD (active)b,d 400 (4.9) 419 (5.1) 0.49
Osteoporosisa 451 (5.5) 512 (6.2) 0.038
Pneumoniab 75 (0.9) 113 (1.4) 0.006
anxiety, depression 373 (4.5) 381 (4.6) 0.763
Charlson comorbidity index scoreb
0 5,610 (68.2) 5,657 (68.8) 0.477
1–4 1,756 (21.4) 1,736 (21.1)
5–9 318 (3.9) 334 (4.1)
$10 541 (6.6) 498 (6.1)
Co-medications
nsaIDsc 3,368 (41.0) 3,474 (42.2) 0.087
Paracetamolc 3,129 (38.0) 3,229 (39.3) 0.103
Beta blockersc 1,080 (13.1) 1,016 (12.4) 0.127
statinsc 2,518 (30.6) 2,640 (32.1) 0.027
Other measures of COPD severity
mMrC score (closest to index date) ,0.001
non-missing 6,572 (79.9) 6,654 (80.9)
0–1 3,863 (58.8) 3,765 (56.6)
$2 2,709 (41.2) 2,889 (43.4)
gOlD grade (closest to index date) not tested
non-missing 7,726 (93.9) 7,791 (94.7)
a 717 (9.3) 717 (9.2)
B 4,796 (62.1) 4,788 (61.5)
C 1,903 (24.6) 1,918 (24.6)
D 310 (4.0) 368 (4.7)
Notes: aWith a diagnostic code recorded at any time prior to or at the last extraction date; bcalculated for the baseline period including the last extraction date; casthma 
patients exclude those with asthma resolved codes; dincludes prescriptions to treat the comorbidity within the baseline period and at the last extraction date; eP-values are 
from conditional logistic regression models; gOlD grade was not compared between cohorts as there was a large amount of missing data.
Abbreviations: mMRC, modified Medical Research Council; GOLD, Global initiative for chronic Obstructive Lung Disease – groups based on 2015 GOLD Strategy; GERD, 
gastroesophageal reflux disease; NSAIDs, non-steroidal anti-inflammatory drugs; NA, not applicable (as variable was used for matching).
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Table S2 Combinations of COPD therapy during baseline year in each study cohort
Inhaler therapy n (%)
Similar-devices  
cohort (n=8,225)
Mixed-devices 
cohort (n=8,225)
saBa 3,839 (46.7) 3,775 (45.9)
saMa + saBa 1,075 (13.1) 1,105 (13.4)
laBa ± saMa ± saBa 228 (2.8) 209 (2.5)
laMa ± saMa ± saBa 243 (3.0) 194 (2.4)
laBa + laMa ± saMa ± saBa 8 (0.1) 3 (0.0)
ICs ± saMa ± saBa 2,271 (27.6) 2,150 (26.1)
ICs + laBa ± saMa ± saBa 511 (6.2) 757 (9.2)
ICs + laMa ± saMa ± saBa 8 (0.1) 1 (0.0)
lTra ± saMa ± saBa 17 (0.2) 17 (0.2)
laBa + lTra ± saMa ± saBa 1 (0.0) 0 (0.0)
ICs + lTra ± saMa ± saBa 17 (0.2) 7 (0.1)
ICs + laBa + lTra ± saMa ± saBa 7 (0.1) 7 (0.1)
Abbreviations: saMa, short-acting muscarinic agonist; saBa, short-acting beta agonist; laBa, long-acting beta agonist; laMa, long-acting muscarinic antagonist; 
ICs, inhaled corticosteroid; lTra, leukotriene receptor antagonist.
Table S3 Combinations of COPD therapy during outcome year in each study cohort
Inhaler therapy n (%)
Similar-devices  
cohort (n=8,225)
Mixed-devices  
cohort (n=8,225)
laBa ± saMa ± saBa 604 (7.3) 336 (4.1)
laMa ± saMa ± saBa 471 (5.7) 1,136 (13.8)
laBa + laMa ± saMa ± saBa 51 (0.6) 250 (3.0)
ICs ± saMa ± saBa 2,464 (30.0) 653 (7.9)
ICs + laBa ± saMa ± saBa 3,680 (44.7) 2,859 (34.8)
ICs + laMa ± saMa ± saBa 90 (1.1) 498 (6.1)
ICs + laBa + laMa ± saMa ± saBa 780 (9.5) 2,358 (28.7)
laBa + lTra ± saMa ± saBa 0 (0.0) 2 (0.0)
laMa + lTra ± saMa ± saBa 4 (0.1) 3 (0.0)
ICs + lTra ± saMa ± saBa 12 (0.2) 3 (0.0)
ICs + laMa + lTra ± saMa ± saBa 4 (0.1) 3 (0.0)
ICs + laBa + laMa + lTra ± saMa ± saBa 11 (0.1) 48 (0.6)
ICs + laBa + lTra ± saMa +/i saBa 53 (0.6) 76 (0.9)
Others 1 (0.0) 0 (0.0)
Abbreviations: saMa, short-acting muscarinic agonist; saBa, short-acting beta agonist; laBa, long-acting beta agonist; laMa, long-acting muscarinic antagonist; 
ICs, inhaled corticosteroid; lTra, leukotriene receptor antagonist.
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 
Figure S1 effect of similar versus mixed devices on primary and secondary COPD outcomes – alternative categorization of devices.
Notes: aIrr adjusted by COPD consultations, use of antibiotics, statins and paracetamol. Or adjusted by saBa dosage, use of statins, beta-blockers and paracetamol. 
n=7,545 in each cohort, for this categorization of devices.
Abbreviations: CI, confidence interval; SABA, short-acting beta agonist.
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 
Figure S2 effect of similar versus mixed devices on primary and secondary COPD outcomes – largest treatment combination subgroup.
Notes: aIrr adjusted by antibiotics courses, asthma diagnosis and use of paracetamol. Or adjusted by saBa dosage, use of statins, beta-blockers and paracetamol. n=3,680 
(44.7%) in similar-devices cohort and n=2,859 (34.8%) in mixed-devices cohort.
Abbreviations: CI, confidence interval; SABA, short-acting beta agonist.
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Figure S3 effect of similar versus mixed devices on primary and secondary COPD outcomes – alternative categorization of devices and largest treatment combination 
subgroup.
Notes: aIrr adjusted by antibiotics courses, asthma diagnosis and use of paracetamol. Or adjusted by saBa dosage, use of statins, beta-blockers and paracetamol. n=3,762 
(49.9%) in similar-devices cohort and n=2,577 (34.2%) in mixed-devices cohort.
Abbreviations: CI, confidence interval; SABA, short-acting beta agonist.
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